This subtype is associated with a lower mutational burden compared to other melanoma types, which can complicate treatment strategies, as TWT melanomas often do not respond well to targeted therapies that are effective in BRAF or NRAS mutant melanomas. The gene discussed is NRAS; the disease is melanoma.